US Biologic, a leading oral vaccine and therapeutic delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,65,360 entitled “Composition & Method for Reducing Zoonotic Infectious Diseases.” The patent extends the US Biologic OrisBio™ oral-delivery technology platform in the creation of orally delivered vaccines.
This patent complements another US Biologic patent (“Oral Vaccine for Borrelia [Lyme disease]”, U.S. Patent No. 8,821,893), which is the basis of US Biologic’s orally delivered Lyme vaccine for wildlife that is undergoing the USDA licensure process for commercialization. Whereas the Lyme patent focuses on the prevention of Lyme disease, this additional patent expands the platform to support multiple vaccines against zoonotic disease.
“Zoonotic diseases include all diseases passed to humans by animals,” says Dr. Steve Zatechka, PhD, MBA, the patent’s primary contributing inventor and the company’s Chief Operating Officer. “This patent covers the creation of a wide range of preventative interventions.”
According to the CDC, “Scientists estimate that more than 6 out of every 10 known infectious diseases in people are spread from animals, and 3 out of every 4 new or emerging infectious diseases in people are spread from animals.” Further, according to the World Health Organization, an estimated 2.7M people die each year, globally, due to zoonotic disease.
“This patent broadens the OrisBio platform and demonstrates US Biologic’s expertise in oral-delivery and commitment to the prevention of zoonotic disease,” says Mason Kauffman, company CEO. “We will continue to aggressively file and earn patents in this space, to expand our global disease prevention impact.” US Biologic currently has several other patent applications pending in the U.S., as well as Canada, China, and the European Union.
About US Biologic
US Biologic "Delivers Disease Prevention®”. The company’s proprietary oral-delivery system is changing global disease prevention, allowing safe, effective, and cost-efficient delivery of a variety of preventative therapeutics (vaccine and antimicrobial) to wildlife, companion animals, and food animals. US Biologic works with world-renowned experts, placing their proven technologies into its oral-delivery system and then commercializes those new products by providing necessary funding, regulatory support, manufacturing, and distribution expertise. Its board of directors include leaders who have served as a CDC director, a CEO of Sanofi Pasteur, and a Secretary of the U.S. Health & Human Services, respectively.
About the OrisBio Platform
OrisBio is US Biologic’s proprietary biotechnology platform that is changing global disease prevention, delivering a variety of preventative therapeutics (vaccines and antimicrobials) to wildlife, companion animals, and food animals. More information can be found on the OrisBio platform website.
